Objective: To describe the clinical effect and safety of low-dose buprenorphine, a κ-opioid receptor antagonist, for treatment-resistant depression (TRD) in midlife and older adults.
Method: In an 8-week open-label study, buprenorphine was prescribed for 15 adults aged 50 years or older with TRD, diagnosed with the Structured Clinical Interview for DSM-IV, between June 2010 and June 2011. The titrated dose of buprenorphine ranged from 0.2-1.6 mg/d. We assessed clinical change in depression, anxiety, sleep, positive and negative affect, and quality of life. The Montgomery-Asberg Depression Rating scale (MADRS) served as the main outcome measure. Tolerability was assessed by documenting side effects and change in vital signs, weight, and cognitive function. Clinical response durability was assessed 8 weeks after discontinuation of buprenorphine.
Results: The mean dose of buprenorphine was 0.4 mg/d (mean maximum dose = 0.7 mg/d). The mean depression score (MADRS) at baseline was 27.0 (SD = 7.3) and at week 8 was 9.5 (SD = 9.5). A sharp decline in depression severity occurred during the first 3 weeks of exposure (mean change = -15.0 [SD = 7.9]). Depression-specific items measuring pessimism and sadness indicated improvement during exposure, supporting a true antidepressant effect. Treatment-emergent side effects (in particular, nausea and constipation) were not sustained, vital signs and weight remained stable, and executive function and learning improved from pretreatment to posttreatment.
Conclusion: Low-dose buprenorphine may be a novel-mechanism medication that provides a rapid and sustained improvement for older adults with TRD. Placebo-controlled trials of longer duration are required to assess efficacy, safety, and physiologic and psychological effects of extended exposure to this medication.
Trial Registration: ClinicalTrials.gov identifier: NCT01071538.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4157317 | PMC |
| http://dx.doi.org/10.4088/JCP.13m08725 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Managing Dual Dependencies: A Case Study of Concurrent Low-Dose Buprenorphine Induction and Rapid Phenobarbital Taper.
J Psychoactive Drugs
January 2025
McGaw Medical Center, Northwestern University Feinberg School of Medicine, Chicago, IL, USA.
Co-occurring substance use disorders are common in medical settings, yet limited literature exists on concomitant pharmacological management. We present a case where low-dose buprenorphine induction (LDBI) and rapid phenobarbital taper were performed concurrently in a hospital setting to manage co-occurring opioid dependence (on chronic methadone maintenance therapy) and benzodiazepine dependence (prescribed alprazolam). The simultaneous management was well-tolerated and completed with minimal complications, successfully enabling candidacy for the patient's preferred disposition.
View Article and Find Full Text PDFBrain region-specific neural activation by low-dose opioid promotes social behavior.
JCI Insight
December 2024
Laboratory of Molecular Neuropharmacology, Graduate School of Pharmaceutical Sciences, and.
The opioid system plays crucial roles in modulating social behaviors in both humans and animals. However, the pharmacological profiles of opioids regarding social behavior and their therapeutic potential remain unclear. Multiple pharmacological, behavioral, and immunohistological c-Fos mapping approaches were used to characterize the effects of μ-opioid receptor agonists on social behavior and investigate the mechanisms in naive mice and autism spectrum disorder-like (ASD-like) mouse models, such as prenatally valproic acid-treated mice and Fmr1-KO mice.
View Article and Find Full Text PDFMethadone-Buprenorphine Transfers Using Low Dosing of Buprenorphine: An Open-Label, Nonrandomized Clinical Trial.
J Addict Med
December 2024
From the Alcohol and Drug Services St Vincent's Hospital, Sydney, Australia (CT); Sydney Local Health District Drug Health Services, Sydney, Australia (CT, JB, NJ, PH); University of Sydney, Sydney, Australia (CT); Drug Health Services, South Western Sydney Local Health District, Sydney, Australia (RH); Northern Sydney Local Health District, Drug & Alcohol Service, Sydney, Australia (NM); Drug and Alcohol Clinical Services, Hunter New England Local Health District, Newcastle, Australia (CI); South Eastern Sydney Local Health District, Drug and Alcohol Services, Sydney, Australia (RP, NL); UNSW Sydney (RP); Division Addiction Medicine, Central Clinical School; South Eastern Sydney Local Health District, Drug and Alcohol Services, NSW Drug and Alcohol Clinical Research and Improvement Network (DACRIN), Sydney, Australia (LM, NL, PH); NSW Poisons Centre, Sydney, Australia (NB); Edith Collins Centre, Royal Prince Alfred Hospital, Sydney, NSW, Australia (NB, VP, PH); Clinical Pharmacology and Toxicology Research Group, Biomedical Informatics & Digital Health, Sydney Medical School, University of Sydney, Sydney, Australia (NB, VP); NSW Health Speciality of Addiction Medicine, Faculty of Medicine and Health, University of Sydney, Sydney, NSW, Australia (NL); and Faculty of Health and Medicine University of Sydney, Sydney, Australia (NJ, PH).
Aims: To compare a low-dosing protocol to standard practice for methadone-buprenorphine transfers.
Methods: We undertook a nonrandomized open-label clinical trial across 8 sites from NSW, Australia. Participants prescribed methadone wishing to transfer to buprenorphine could either choose or be randomized to a low-dose transfer or standard care transfer as per NSW health guidelines.
24-Hour Induction of Transdermal Buprenorphine to Buprenorphine Extended-Release.
J Psychoactive Drugs
November 2024
Pharmacokinetics Modeling and Simulation Laboratory, Faculty of Pharmaceutical Sciences, University of British Columbia, Vancouver, BC, Canada.
Buprenorphine is an effective treatment for opioid use disorder but can be slow when using a standard low-dose titration protocol to avoid precipitated withdrawal. This presents a substantial practical barrier in clinical practice. Recent low-dose induction strategies have attempted to simplify and shorten the process required for successful induction, including our own transdermal buprenorphine method, which achieves induction to sublingual buprenorphine/naloxone after 48 h.
View Article and Find Full Text PDFBuprenorphine 'microdosing' method for switching patients with opioid dependence from methadone to buprenorphine.
BMJ Case Rep
November 2024
National Drug Dependence Treatment Centre, All India Institute of Medical Sciences New Delhi, New Delhi, Delhi, India
Various factors limit the acceptability of methadone as an opioid agonist treatment (OAT), in which case, buprenorphine becomes the preferred alternative. The classical approach is to gradually taper methadone to a low dose and buprenorphine is initiated after some opioid-free period, which generally takes weeks. A novel approach known as 'microdosing' or the 'Bernese method' might serve as a valuable alternative.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!